BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 7905785)

  • 21. Direct evidence for functional coupling of the vasoactive intestinal peptide receptor to Gi3 in native lung membranes.
    Diehl NL; Kermode JC; Shreeve SM
    Mol Pharmacol; 1996 Sep; 50(3):624-30. PubMed ID: 8794903
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Characterization of vasoactive intestinal peptide receptors on rat alveolar macrophages.
    Sakakibara H; Shima K; Said SI
    Am J Physiol; 1994 Sep; 267(3 Pt 1):L256-62. PubMed ID: 7943252
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In vitro and in vivo studies of three radiolabelled somatostatin analogues: 123I-octreotide (OCT), 123I-Tyr-3-OCT and 111In-DTPA-D-Phe-1-OCT.
    Virgolini I; Angelberger P; Li S; Yang Q; Kurtaran A; Raderer M; Neuhold N; Kaserer K; Leimer M; Peck-Radosavljevic M; Scheithauer W; Niederle B; Eichler HG; Valent P
    Eur J Nucl Med; 1996 Oct; 23(10):1388-99. PubMed ID: 8781146
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Investigation of cancer cell lines for peptide receptor-targeted drug development.
    Sun L; Luo J; Mackey LV; Morris LM; Franko-Tobin LG; LePage KT; Coy DH
    J Drug Target; 2011 Sep; 19(8):719-30. PubMed ID: 21830941
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Combined ultrastructural and biochemical study of cellular processing of vasoactive intestinal peptide and its receptors in human colonic carcinoma cells in culture.
    Hejblum G; Gali P; Boissard C; Astesano A; Marie JC; Anteunis A; Hui Bon Hoa D; Rosselin G
    Cancer Res; 1988 Nov; 48(21):6201-10. PubMed ID: 2844402
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Vasoactive intestinal peptide control of cyclic adenosine 3':5'-monophosphate levels in seven human colorectal adenocarcinoma cell lines in culture.
    Laburthe M; Rousset M; Chevalier G; Boissard C; Dupont C; Zweibaum A; Rosselin G
    Cancer Res; 1980 Jul; 40(7):2529-33. PubMed ID: 6248206
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inhibition of vasoactive intestinal peptide (VIP) binding on human melanoma cells IGR39 by nitric oxide: cGMP is not involved.
    Fouchier F; Pichon J; Forget P
    Eur J Cell Biol; 1994 Jun; 64(1):71-7. PubMed ID: 7957315
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Vasoactive intestinal peptide- and adrenocorticotropin-stimulated adenyl cyclase in cultured adrenal tumor cells: evidence for a specific vasoactive intestinal peptide receptor.
    Birnbaum RS; Alfonzo M; Kowal J
    Endocrinology; 1980 Apr; 106(4):1270-5. PubMed ID: 6244149
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Transactivation of HER2 by vasoactive intestinal peptide in experimental prostate cancer: Antagonistic action of an analog of growth-hormone-releasing hormone.
    Sotomayor S; Carmena MJ; Schally AV; Varga JL; Sánchez-Chapado M; Prieto JC; Bajo AM
    Int J Oncol; 2007 Nov; 31(5):1223-30. PubMed ID: 17912451
    [TBL] [Abstract][Full Text] [Related]  

  • 30. VIP enhances synaptic transmission to hippocampal CA1 pyramidal cells through activation of both VPAC1 and VPAC2 receptors.
    Cunha-Reis D; Ribeiro JA; Sebastião AM
    Brain Res; 2005 Jul; 1049(1):52-60. PubMed ID: 15935995
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A lymphocyte-generated fragment of vasoactive intestinal peptide with VPAC1 agonist activity and VPAC2 antagonist effects.
    Summers MA; O'Dorisio MS; Cox MO; Lara-Marquez M; Goetzl EJ
    J Pharmacol Exp Ther; 2003 Aug; 306(2):638-45. PubMed ID: 12750439
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Properties of the pituitary adenylate cyclase-activating polypeptide I and II receptors, vasoactive intestinal peptide1, and chimeric amino-terminal pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal peptide1 receptors: evidence for multiple receptor states.
    Van Rampelbergh J; Gourlet P; De Neef P; Robberecht P; Waelbroeck M
    Mol Pharmacol; 1996 Dec; 50(6):1596-604. PubMed ID: 8967982
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Characterization of vasoactive intestinal peptide receptors in rabbit ciliary processes.
    Horio B; Law NM; Rosenzweig SA
    Invest Ophthalmol Vis Sci; 1995 Jan; 36(1):192-9. PubMed ID: 7529752
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mutagenesis of N-glycosylation sites in the human vasoactive intestinal peptide 1 receptor. Evidence that asparagine 58 or 69 is crucial for correct delivery of the receptor to plasma membrane.
    Couvineau A; Fabre C; Gaudin P; Maoret JJ; Laburthe M
    Biochemistry; 1996 Feb; 35(6):1745-52. PubMed ID: 8639654
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Restricted localization of functional vasoactive intestinal peptide (VIP) receptors in in vitro differentiated human colonic adenocarcinoma cells (HT29-D4).
    Fantini J; Martin JM; Luis J; Rémy L; Tirard A; Marvaldi J; Pichon J
    Eur J Cell Biol; 1988 Aug; 46(3):458-65. PubMed ID: 2846304
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Properties of vasoactive intestinal peptide-receptor interaction in rat liver membranes.
    Guerrero JM; Prieto JC; Ramírez-Cárdenas R; Calvo JR; Goberna R
    Rev Esp Fisiol; 1981 Mar; 37(1):1-8. PubMed ID: 6113623
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evidence for a direct interaction between the Thr11 residue of vasoactive intestinal polypeptide and Tyr184 located in the first extracellular loop of the VPAC2 receptor.
    Nachtergael I; Vertongen P; Langer I; Perret J; Robberecht P; Waelbroeck M
    Biochem J; 2003 Mar; 370(Pt 3):1003-9. PubMed ID: 12475394
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Somatostatin receptor subtype specificity and in vivo binding of a novel tumor tracer, 99mTc-P829.
    Virgolini I; Leimer M; Handmaker H; Lastoria S; Bischof C; Muto P; Pangerl T; Gludovacz D; Peck-Radosavljevic M; Lister-James J; Hamilton G; Kaserer K; Valent P; Dean R
    Cancer Res; 1998 May; 58(9):1850-9. PubMed ID: 9581824
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The vasoactive intestinal peptide-receptor system is involved in human glioblastoma cell migration.
    Cochaud S; Chevrier L; Meunier AC; Brillet T; Chadéneau C; Muller JM
    Neuropeptides; 2010 Oct; 44(5):373-83. PubMed ID: 20638719
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In vitro identification of vasoactive intestinal peptide receptors in human tumors: implications for tumor imaging.
    Reubi JC
    J Nucl Med; 1995 Oct; 36(10):1846-53. PubMed ID: 7562054
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.